Inscinstech Co., Ltd., a leading intelligent technology company based in Suzhou, has successfully completed a C-series financing round worth hundreds of millions of RMB. The round was led by the Service Trade Innovation Development Guidance Fund, with additional investments from ORIZA Holdings and LUCION, an existing shareholder. This financing marks a significant milestone in Inscinstech’s rapid development history.
Funding and Strategic Expansion
The funds raised will be used to innovate and develop new product pipelines, expand production capabilities, and inject strong momentum into Inscinstech’s global strategic layout in the fields of cell and gene therapy (CGT), antibodies, and vaccines. This strategic move will further enhance the company’s position in the biopharmaceutical industry, particularly in the areas of chemical, manufacturing, and control (CMC) solutions.
Company Background and Achievements
Founded in 2017, Inscinstech specializes in providing comprehensive solutions for biopharmaceutical CMC, covering upstream and downstream processes as well as laboratory analysis. The company has established partnerships with over 1,000 clients globally, including enterprises, universities, and research institutes in the fields of CGT, nucleic acid drugs, antibodies, vaccines, and in vitro diagnostics (IVD). Inscinstech has also formed deep strategic cooperation with several key clients to jointly promote the development and innovation of the biopharmaceutical industry.
Research and Development Capabilities
Inscinstech has established two major research and development centers in Suzhou and Beijing, gathering a world-class R&D technical team. The core members of the team come from top global life science instrument companies. The company also operates a production and manufacturing base of over 10,000 square meters in Suzhou, ensuring product quality and timely delivery.-Fineline Info & Tech
Leave a Reply